Harbor Capital Advisors Inc. Invests $82,000 in Exelixis, Inc. $EXEL

Harbor Capital Advisors Inc. purchased a new position in Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,853 shares of the biotechnology company’s stock, valued at approximately $82,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Byrne Asset Management LLC raised its stake in shares of Exelixis by 129.0% during the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 400 shares in the last quarter. Hemington Wealth Management grew its position in Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 522 shares during the period. Bartlett & CO. Wealth Management LLC acquired a new position in Exelixis in the first quarter worth $37,000. Costello Asset Management INC acquired a new position in shares of Exelixis during the first quarter valued at $39,000. Finally, Harbour Investments Inc. lifted its stake in Exelixis by 900.0% in the first quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 990 shares during the period. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Price Performance

Exelixis stock opened at $40.10 on Friday. The firm has a market capitalization of $10.79 billion, a P/E ratio of 19.28, a price-to-earnings-growth ratio of 0.83 and a beta of 0.32. The company’s 50-day moving average is $39.52 and its 200 day moving average is $39.69. Exelixis, Inc. has a 1-year low of $25.17 and a 1-year high of $49.62.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. Exelixis’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. Research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on EXEL. Jefferies Financial Group set a $50.00 price objective on Exelixis and gave the stock a “buy” rating in a report on Tuesday, June 24th. Guggenheim restated a “buy” rating and set a $45.00 price objective on shares of Exelixis in a research note on Tuesday, July 29th. Wall Street Zen lowered Exelixis from a “buy” rating to a “hold” rating in a research note on Monday, September 15th. The Goldman Sachs Group initiated coverage on Exelixis in a report on Wednesday. They set a “buy” rating and a $47.00 target price on the stock. Finally, Stephens raised Exelixis from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $29.00 to $60.00 in a research note on Tuesday, June 24th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.42.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.